CA
PLX icon

CapWealth Advisors’s Protalix BioTherapeutics PLX Stock Holding History

CapWealth Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-40
Closed -$1K – 387
2014
Q2 		$1K Buy
+40
New +$1.61K ﹤0.01% 342

Other funds holding PLX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

CapWealth Advisors's PLX Position: Q3 2014 in Review

CapWealth Advisors sold out of Protalix BioTherapeutics (PLX) in Q3 2014, closing a stake of 40 shares — an estimated $1K sold.

CapWealth Advisors first reported a position in PLX in Q2 2014 and held it in 1 quarter. The position peaked at $1K in Q2 2014. 43 funds tracked by Wall St. Rank hold PLX as of Q3 2014.

  • CapWealth Advisors reported no remaining Protalix BioTherapeutics position as of Q3 2014 after selling out during the quarter.
  • CapWealth Advisors sold 40 Protalix BioTherapeutics shares in Q3 2014, an estimated $1K.
  • CapWealth Advisors first reported a position in Protalix BioTherapeutics in Q2 2014 and held it in 1 quarter.
  • CapWealth Advisors's Protalix BioTherapeutics position peaked at $1K in Q2 2014.
  • 43 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2014.

Based on CapWealth Advisors's 13F filing for Q3 2014, filed 12 Nov 2014.